X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (892) 892
oncology (840) 840
female (665) 665
chemotherapy (584) 584
aged (533) 533
index medicus (526) 526
weekly paclitaxel (522) 522
middle aged (501) 501
antineoplastic combined chemotherapy protocols - therapeutic use (405) 405
adult (396) 396
male (347) 347
cancer (343) 343
treatment outcome (321) 321
paclitaxel (291) 291
paclitaxel - administration & dosage (287) 287
drug administration schedule (263) 263
docetaxel (237) 237
breast neoplasms - drug therapy (221) 221
cisplatin (221) 221
phase-ii trial (220) 220
carboplatin (201) 201
lung neoplasms - drug therapy (200) 200
antineoplastic combined chemotherapy protocols - adverse effects (197) 197
aged, 80 and over (175) 175
trial (174) 174
breast cancer (164) 164
carcinoma, non-small-cell lung - drug therapy (164) 164
antineoplastic agents - therapeutic use (161) 161
disease-free survival (161) 161
care and treatment (154) 154
therapy (153) 153
pharmacology & pharmacy (150) 150
neoplasm staging (143) 143
breast neoplasms - pathology (135) 135
medicine & public health (135) 135
paclitaxel - adverse effects (135) 135
carcinoma (133) 133
survival rate (126) 126
weekly docetaxel (123) 123
antineoplastic combined chemotherapy protocols - administration & dosage (117) 117
combination (117) 117
phase-ii (117) 117
taxoids - administration & dosage (117) 117
hematology, oncology and palliative medicine (114) 114
metastasis (114) 114
survival analysis (111) 111
research (110) 110
randomized-trial (108) 108
carboplatin - administration & dosage (107) 107
ovarian neoplasms - drug therapy (106) 106
neoplasm metastasis (105) 105
cisplatin - administration & dosage (104) 104
phase-iii trial (104) 104
lung neoplasms - pathology (103) 103
retrospective studies (102) 102
radiotherapy (101) 101
prognosis (100) 100
antineoplastic agents, phytogenic - administration & dosage (97) 97
ovarian cancer (97) 97
survival (96) 96
clinical trials (95) 95
doxorubicin (94) 94
gemcitabine (93) 93
deoxycytidine - analogs & derivatives (92) 92
obstetrics & gynecology (92) 92
dose-response relationship, drug (86) 86
drug therapy (85) 85
infusions, intravenous (84) 84
antineoplastic agents - administration & dosage (83) 83
combined modality therapy (83) 83
antineoplastic agents (82) 82
carcinoma, non-small-cell lung - pathology (81) 81
neoplasm recurrence, local - drug therapy (81) 81
vinorelbine (81) 81
bevacizumab (80) 80
antimitotic agents (77) 77
deoxycytidine - administration & dosage (77) 77
open-label (77) 77
paclitaxel - therapeutic use (75) 75
analysis (74) 74
cancer research (73) 73
combination chemotherapy (73) 73
follow-up studies (73) 73
non-small cell lung cancer (73) 73
cell lung-cancer (72) 72
cyclophosphamide (72) 72
lung cancer, non-small cell (69) 69
metastatic breast cancer (68) 68
clinical trials as topic (67) 67
trastuzumab (67) 67
disease progression (66) 66
health aspects (66) 66
toxicity (65) 65
fluorouracil - administration & dosage (64) 64
lung cancer (63) 63
taxoids - therapeutic use (63) 63
weekly (63) 63
oncology, experimental (62) 62
radiation-therapy (62) 62
antineoplastic agents, phytogenic - therapeutic use (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1104) 1104
Japanese (10) 10
French (9) 9
German (8) 8
Korean (3) 3
Chinese (2) 2
Italian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2016, Volume 70, pp. 146 - 155
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 11, pp. 2768 - 2772
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 02/2019, Volume 83, Issue 2, pp. 301 - 318
Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in... 
Expert meeting | Breast cancer | Neuropathy | Nab-paclitaxel | Weekly schedule | Antimitotic agents | Medical colleges | Care and treatment | Cancer patients | Algorithms | Metastasis | Antineoplastic agents | Effectiveness | Patients | ErbB-2 protein | Subgroups | Metastases | Literature reviews | Scientific papers | Quality | Paclitaxel | Breast | Safety | Tumors | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 987 - 994
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article